Combination therapeutic regimen for treating breast cancer and inducing apoptosis in breast cancer cells, comprises resveratrol and/or a derivative as a deoxyribonucleic acid-damaging agent, and an olaparib and/or a derivative as a deoxyribonucleic acid repair inhibitor
	SINHA S; KUNDU C N
	2024-11-13
专利权人	KALINGA IND TECHNOLOGY INST (KALI-Non-standard)
申请日期	2024-11-13
专利号	IN202431087553-A
成果简介	NOVELTY - Combination therapeutic regimen comprises a resveratrol and/or a derivative as a deoxyribonucleic acid (DNA)-damaging agent, and an olaparib and/or a derivative as a DNA repair inhibitor. USE - Combination therapeutic regimen for treating breast cancer and inducing apoptosis in breast cancer cells (all claimed). No biological data given. ADVANTAGE - The combination therapeutic regimen utilizes resveratrol that induces double-stranded breaks (DSBs) in the DNA of breast cancer cells, and olaparib that inhibits poly (ADP-ribose) polymerase (PARP) activity and prevents the repair of DNA damage in cells, leading to cell death, exhibits synergistic effect, enhances DNA damage, promotes cell cycle arrest, downregulates DNA repair proteins, and increases apoptosis in breast cancer cells compared to individual treatments with resveratrol or olaparib alone, minimizes toxicity to normal, healthy cells and increases the bioavailability of the therapeutic regimen. The combination therapeutic regimen utilizes resveratrol, a naturally occurring product, that allows the production of the therapeutic agents in large quantities, which reduces the overall cost of the therapy while maintaining efficacy, exhibits reduced dosage of each agent, lowering the risk of side effects and minimizing overall toxicity while maintaining effective therapeutic outcomes in treating breast cancer, DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for enhancing the therapeutic efficacy of DNA-damaging agents in treating breast cancer, comprising the sequential administration of resveratrol at a concentration of 10 µM for 6 hours to induce DNA damage in breast cancer cells, and olaparib at a concentration of 4 nM for 24 hours to inhibit the repair of the induced DNA damage, thus causing accumulation of unrepaired DNA lesions and leading to cancer cell apoptosis.
IPC 分类号	A61K-031/05 ; A61K-031/495 ; A61K-031/498 ; A61K-031/502 ; A61P-035/00
国家	印度
专业领域	医药卫生
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/14547
专题	中国科学院新疆生态与地理研究所
作者单位	KALINGA IND TECHNOLOGY INST (KALI-Non-standard)
推荐引用方式 GB/T 7714	SINHA S,KUNDU C N. Combination therapeutic regimen for treating breast cancer and inducing apoptosis in breast cancer cells, comprises resveratrol and/or a derivative as a deoxyribonucleic acid-damaging agent, and an olaparib and/or a derivative as a deoxyribonucleic acid repair inhibitor. IN202431087553-A[P]. 2024.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。